Echinocandins

Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.

Also Known As:

Networked: 324 relevant articles (45 outcomes, 33 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Walsh, Thomas J: 17 articles (12/2015 - 01/2002)
2.	Roilides, Emmanuel: 9 articles (12/2015 - 07/2007)
3.	Lewis, Russell E: 8 articles (09/2015 - 05/2008)
4.	Kontoyiannis, Dimitrios P: 8 articles (08/2014 - 12/2003)
5.	Glöckner, A: 6 articles (08/2015 - 05/2010)
6.	Kauffman, Carol A: 5 articles (10/2015 - 04/2004)
7.	Drew, Richard H: 5 articles (08/2011 - 05/2006)
8.	Petraitis, Vidmantas: 4 articles (12/2015 - 01/2002)
9.	Katragkou, Aspasia: 4 articles (12/2015 - 06/2011)
10.	Viscoli, Claudio: 4 articles (12/2013 - 01/2010)

Related Diseases

1.	Infection 03/01/2007 - "Overall, the three echinocandins are relatively safe and effective agents for the treatment of Candida infections." 12/01/2009 - "The three echinocandins were similarly effective in the treatment of experimental disseminated infections with C. " 12/01/2008 - "The echinocandins are a new class of antifungal agent that has shown promising results in the treatment of numerous invasive fungal infections. " 11/01/2006 - "The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. " 07/15/2006 - "Echinocandins are a new class of drugs that have shown promising results in treating a variety of fungal infections. "
2.	Invasive Candidiasis 10/01/2007 - "The echinocandins have potent fungicidal activity against most Candida species, but there are few data comparing the safety and efficacy of echinocandins in the treatment of invasive candidiasis. " 07/01/2014 - "Echinocandins are employed as the first-line treatment for invasive candidiasis until the fungal species is determined and confirmed by clinical diagnosis. " 01/01/2014 - "Echinocandins are indicated as first-line treatment for invasive candidiasis in moderate to severe illness. " 08/01/2008 - "The echinocandins as a class offer an advance in the treatment of invasive candidiasis, an additional option for prophylaxis and an attractive choice for the study of combination antifungal therapy. " 12/01/2015 - "The current standard of treatment of invasive candidiasis with echinocandins requires once-daily therapy. "
3.	Aspergillosis 01/01/2015 - "However, studies demonstrating the clinical effectiveness of echinocandins in comparison with antifungals currently recommended for first-line treatment of invasive aspergillosis are still lacking. " 10/01/2006 - "By contrast, the demonstrated efficacy of the echinocandins for the treatment of invasive aspergillosis has been based on historically controlled salvage treatment trials in patients failing or intolerant of other therapies. " 07/01/2007 - "Combination therapy with echinocandins plus other licensed antifungal therapy shows promise in treating invasive aspergillosis. " 12/01/2011 - "Current role of echinocandins in the management of invasive aspergillosis." 01/01/2009 - "Echinocandins represent a safe and well tolerated option for the therapy of invasive aspergillosis in patients who are unable to tolerate other agents or have refractory disease. "
4.	Critical Illness (Critically Ill) 04/01/2012 - "Echinocandins are the first line treatment for IC in critically ill patients with mild or severe illness. " 12/01/2015 - "To conclude, adminstration of echinocandins in this observed study population is safe, even in severely critically ill patients if application rules of these agents are followed. " 12/01/2015 - "Therefore, treatment guidelines recommend echinocandins as first-line antifungals in critically ill patients to improve patient outcomes. " 03/01/2015 - "Echinocandins have become the agents of choice for early and specific antifungal treatment in critically ill patients. " 02/01/2014 - "Echinocandins have become the agents of choice for early and specific antifungal treatment in critically ill patients. "
5.	Candidemia 11/01/2015 - "Echinocandins have in vitro activity against most Candida spp. and are the first-line agents in the treatment of candidemia. " 10/01/2015 - "The antifungal drugs used to treat candidemia are mainly the echinocandins, however some isolates may be resistant to these drugs. " 09/01/2015 - "The diminished macrophage inflammatory response to isolates that caused persistent candidemia and differential immunopharmacologic activity of echinocandins among FKS mutants suggest that certain strains of C. " 10/01/2014 - "The use of echinocandins as primary therapy for candidemia appears to be associated with better outcomes." 09/15/2014 - "Echinocandins are recommended for Candia glabrata candidemia. "

Related Drugs and Biologics

1.	Amphotericin B (Amphotericin)
2.	voriconazole (Vfend)
3.	caspofungin (Cancidas)
4.	anidulafungin
5.	Azoles
6.	Triazoles
7.	Fluconazole (Zonal)
8.	micafungin (FK463)
9.	Antifungal Agents
10.	posaconazole

Related Therapies and Procedures

1.	Salvage Therapy
2.	Transplants (Transplant)
3.	Catheters
4.	Transplantation (Transplant Recipients)
5.	Hematopoietic Stem Cell Transplantation